Clinical

Nipocalimab showed rapid responses within 1 week in warm autoimmune hemolytic anemia (wAIHA), as well as a favorable safety profile.

Tarik Asselah, MD, PhD, explains why HDV RNA suppression deepened through 2 years with tobevibart plus elebsiran.

This new analysis offers some of the most rigorous real-world data to guide treatment decisions for TP53 wild-type chronic lymphocytic leukemia.

Pooled TETON trial data showed inhaled treprostinil preserved lung function in IPF, supporting an FDA submission planned for 2026.

Baseline QOL is an independent prognostic factor for survival in AML, with global QOL carrying the largest HR, according to Fabio Efficace, PhD, MSc.

How health systems break silos with multidisciplinary, patient-centered teams to improve CRM outcomes through coordinated, holistic care.

Clinicians weigh antipsychotic choices with patients, tracking labs and side effects, while navigating insurance and brand-vs-generic variability.

Experts reveal how stigma, misdiagnosis, and cost barriers delay depression, bipolar, and schizophrenia care—and what breaks the crisis cycle.

How combined therapies and proactive, team-based CRM care cut costs, streamline meds, and improve heart, kidney, and metabolic outcomes.

ACP's new obesity guidelines name semaglutide and tirzepatide as first-line drugs in a 4-tier hierarchy, with weight-regain warnings for all agents.

Worse kidney function and higher proteinuria at biopsy predicted significantly greater health care use over 2 years in patients with IgA nephropathy.

In a VESALIUS-CV subgroup analysis, evolocumab cut MACE by 29% in high-risk diabetes, reinforcing intensive LDL lowering for CV risk reduction.

The panelists examined how the scarcity of mental health specialists creates a cascading effect on care capacity, where patients who do not respond to initial primary care treatment face an increasingly narrow pool of expert clinicians equipped to manage complex, refractory cases.

Real-world DME care falls short from missed anti-VEGF loading; sustained delivery, neuroprotection, and better primary care coordination promise gains.

Learn how rare neuroendocrine cancers are diagnosed, why pathology and Ki-67 guide care, and how teams coordinate chemo, trials, support.

New factor XIa inhibitors cut recurrent non-cardioembolic stroke without extra bleeding—plus what milvexian and abilacimab trials reveal.

Experts unpack neuroendocrine carcinoma vs tumors, key pathology markers, and high-risk features shaping prognosis and treatment decisions.

Factor XIa blockers aim to prevent stroke-driving clots with less bleeding; explore leading phase 3 drugs and oral vs IV tradeoffs.

Late-breaking phase 3 SENTRY data show selinexor plus ruxolitinib improves spleen volume, survival, and disease markers in myelofibrosis.

In a MajesTEC-3 subgroup analysis, Tec-Dara showed 77% 3-year PFS vs 0% with standard therapy in functional high-risk R/R MM.

Replacing chemotherapy with blinatumomab improved event-free survival and reduced toxicity in high-risk pediatric ALL, data show.

The phase 3 frontMIND trial showed tafasitamab plus lenalidomide with R-CHOP reduced risk of disease progression or death in high-risk DLBCL.

ADA 2026 featured incretin therapy advances, survodutide phase 3 data in metabolic liver disease, and cardiovascular risk reduction with evolocumab.

Naim Alkhouri, MD, discusses real-world resmetirom data in MASH, GLP-1 combinations, and using ANTICIPATE-NASH in practice.

Although smaller studies have highlighted CAR T differences in access and outcomes, new research shows the full extent of the issue.